Show simple item record

dc.contributor.authorPerez-Olmeda, Mayte 
dc.contributor.authorSaugar, Jose Maria 
dc.contributor.authorFernandez-Garcia, Aurora 
dc.contributor.authorPerez-Gomez, Beatriz 
dc.contributor.authorPollan-Santamaria, Marina 
dc.contributor.authorAvellón, Ana 
dc.contributor.authorPastor-Barriuso, Roberto 
dc.contributor.authorFernandez de Larrea-Baz, Nerea 
dc.contributor.authorMartín, Mariano
dc.contributor.authorCruz, Israel 
dc.contributor.authorSanmartín, Jose L
dc.contributor.authorFedele, Cesare Giovanni 
dc.contributor.authorLeón Paniagua, Jose
dc.contributor.authorMuñoz-Montalvo, Juan F
dc.contributor.authorBlanco, Faustino
dc.contributor.authorYotti-Alvarez, Raquel 
dc.contributor.authorOteo-Iglesias, Jesus
dc.identifier.citationmedRxiv 2021.03.11.21253142;es_ES
dc.description.abstractObjectives To analyse temporal trends in SARS-CoV-2 anti-nucleocapsid IgG throughout the four rounds of the nationwide seroepidemiologic study ENE-COVID (April-November 2020), and to compare the fourth-round results of two immunoassays detecting antibodies against nucleocapsid and to S protein receptor-binding domain (RBD). Methods A chemiluminescent microparticle immunoassay (CMIA) was offered to all participants in the first three rounds (Abbott; anti-nucleocapsid IgG). In the fourth round we offered this test and a chemiluminescence immunoassay (CLIA) (Beckman; anti-RBD IgG) to i) a randomly selected sub-cohort, ii) participants who were IgG-positive in any of the three first rounds; and iii) participants who were IgG-positive in the fourth round by point-of-care immunochromatography. Results Immunoassays involving 10,153 participants (82.2% of people invited to donate samples) were performed in the fourth round. A total of 2595 participants (35.1% of participants with immunoassay results in the four rounds) were positive for anti-nucleocapsid IgG in at least one round. Anti-nucleocapsid IgG became undetectable in 43.3% of participants with positive first-round results. Pneumonia was more frequent in participants with anti-nucleocapsid IgG in all four rounds (11.2%) than those in which IgG became undetectable (2.4%). In fourth round, anti-nucleocapsid and anti-RBD IgG were detected in 5.5% and 5.4% participants of the randomly selected sub-cohort, and in 26.6% and 25.9% participants with at least one previous positive result, respectively. Agreement between techniques was 90.3% (kappa: 0.72). Conclusions The response of IgG to SARS-CoV-2 is heterogeneous and conditioned by infection severity. A substantial proportion of the SARS-CoV-2 infected population may have negative serologic results in the post-infection months.es_ES
dc.titleEvolution of antibodies against SARS-CoV-2 over seven months: experience of the Nationwide Seroprevalence ENE-COVID Study in Spaines_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiología
dc.repisalud.centroISCIII::Escuela Nacional de Sanidad
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional